Pre-market Hot Trades in US Stocks

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026) rose 25.34% in pre-market trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

CDT rose 8.05% in pre-market trading. Based on recent key news:

1. On July 14, CDT Environmental Technology Investment Holdings successfully met the Nasdaq minimum bid requirement. The company's stock price has exceeded the required minimum threshold, ensuring compliance with Nasdaq regulations. This achievement is significant for CDT, marking a positive trend in its stock performance. The company's re-compliance with this requirement reflects investor confidence and may bring further growth opportunities. The market reacted positively to the compliance, driving the stock price up.

Top Gainers in Pre-market US Stocks

Jet.AI rose 969.96% in pre-market trading. Based on recent news:

1. On July 13, Jet.AI completed its merger with flyExclusive. This merger marks the collaboration of two key enterprises and is expected to have a significant impact on the market, driving the stock price sharply upward.

2. On July 14, Jet.AI released new financial expectations. The earnings per share forecast was raised from $0.75 to $1.00, although the revenue expectation was lowered from $2.23 million to $1.10 million, the market remains optimistic about its performance, pushing the stock price up.

3. On July 15, analysts maintained a buy rating. Maxim Group lowered the target price to $80 but still maintained a buy rating, further boosting market confidence. The technology sector is experiencing frequent merger activities, increasing market volatility.

VivoSim Labs rose 85.67% in pre-market trading. Based on recent key news:

1. On July 15, VivoSim Labs announced that its revenue for fiscal year 2027 is expected to grow by over 500%, primarily due to increased demand for its drug safety testing services. This news significantly boosted the stock price.

2. On July 15, VivoSim Labs received a $5 million milestone payment from Eli Lilly for its inflammatory bowel disease drug, which was used on patients for the first time in a mid-stage study. This payment further strengthened the company's financial position.

3. On July 15, VivoSim Labs' technology attracted gene therapy and antibody drug developers, as its lab-cultured human tissue models help predict drug side effects and reduce reliance on animal testing. This technological advantage has enhanced market confidence in the company. The rising demand in the biotechnology sector has driven the stock price up Ernexa Therapeutics pre-market rose 55.94%. Based on recent key news:

4. On July 15, Ernexa Therapeutics successfully replicated the ERNA-101 combination data in a larger-scale preclinical study. This achievement has boosted the company's confidence in advancing the New Drug Application (IND) process, significantly driving up the stock price.

5. On July 15, Ernexa Therapeutics issued a statement reminding investors to remain cautious regarding forward-looking statements; nevertheless, the market remains optimistic about its future development, further propelling the stock price.

6. No other significant news recently. The biotechnology sector has been active lately, with noticeable capital inflows